Stanford University School of Medicine scientists have used bioengineered mice with livers composed largely of human cells to characterize a drug about to enter early-stage clinical development for combating hepatitis C. Tests using the new mouse model accurately predicted significant aspects of the drug’s behavior in humans — including its interaction with another drug and the profile of its major breakdown products in the body (called metabolites) — far more accurately than would have been achieved using current methods.
